Bangyan Wang1, Sudip Thapa1, Ting Zhou1, Huiquan Liu1, Lu Li1, Guang Peng2, Shiying Yu3. 1. Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei Province, People's Republic of China. 2. Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei Province, People's Republic of China. syyu_tjh@163.com.
Abstract
PURPOSE: Cancer-related fatigue (CRF) is a pervasive symptom experienced by cancer patients. Sarcopenia has been suggested as a treatment target of CRF. This study aims to assess the differences of CRF and biochemical markers among different stages of sarcopenia which remain poorly delineated. METHODS: A total of 187 patients were included in this cross-sectional study. Based on muscle mass (skeletal muscle index, SMI), muscle strength (handgrip strength), and physical performance (SARC-F score), patients were divided into four groups (non-sarcopenia, pre-sarcopenia, sarcopenia, and severe sarcopenia). Cancer-related fatigue was measured by the Brief Fatigue Inventory (BFI). Biochemical markers were measured by routine blood tests. RESULTS: The BFI score was significantly associated with sarcopenia stage (r=0.500; P<0.001). Cancer patients in severe sarcopenia group suffered from worse CRF than those in non-sarcopenia, pre-sarcopenia, and sarcopenia groups (P<0.001). In the multivariate linear regression model (R2=0.542), CRF was significantly correlated with SARC-F score (standardized B=0.519; P<0.001) and high-sensitivity C-reactive protein (standardized B=0.389; P=0.004). Serum albumin and cholinesterase were statistically correlated with both sarcopenia stage and CRF. CONCLUSIONS: The significantly increased occurrence and severity of CRF in cancer patients with sarcopenia suggest that sarcopenia may be a crucial target to improve the management of CRF. Circulating albumin and cholinesterase have the potential to predicting sarcopenia as biomarkers.
PURPOSE:Cancer-related fatigue (CRF) is a pervasive symptom experienced by cancerpatients. Sarcopenia has been suggested as a treatment target of CRF. This study aims to assess the differences of CRF and biochemical markers among different stages of sarcopenia which remain poorly delineated. METHODS: A total of 187 patients were included in this cross-sectional study. Based on muscle mass (skeletal muscle index, SMI), muscle strength (handgrip strength), and physical performance (SARC-F score), patients were divided into four groups (non-sarcopenia, pre-sarcopenia, sarcopenia, and severe sarcopenia). Cancer-related fatigue was measured by the Brief Fatigue Inventory (BFI). Biochemical markers were measured by routine blood tests. RESULTS: The BFI score was significantly associated with sarcopenia stage (r=0.500; P<0.001). Cancerpatients in severe sarcopenia group suffered from worse CRF than those in non-sarcopenia, pre-sarcopenia, and sarcopenia groups (P<0.001). In the multivariate linear regression model (R2=0.542), CRF was significantly correlated with SARC-F score (standardized B=0.519; P<0.001) and high-sensitivity C-reactive protein (standardized B=0.389; P=0.004). Serum albumin and cholinesterase were statistically correlated with both sarcopenia stage and CRF. CONCLUSIONS: The significantly increased occurrence and severity of CRF in cancerpatients with sarcopenia suggest that sarcopenia may be a crucial target to improve the management of CRF. Circulating albumin and cholinesterase have the potential to predicting sarcopenia as biomarkers.
Authors: Ollie Minton; Ann Berger; Andrea Barsevick; Fiona Cramp; Martine Goedendorp; Sandra A Mitchell; Patrick C Stone Journal: Cancer Date: 2013-06-01 Impact factor: 6.860
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Karen M Mustian; Gary R Morrow; Jennifer K Carroll; Colmar D Figueroa-Moseley; Pascal Jean-Pierre; Geoffrey C Williams Journal: Oncologist Date: 2007
Authors: Robert D Kilgour; Antonio Vigano; Barbara Trutschnigg; Laura Hornby; Enriqueta Lucar; Simon L Bacon; José A Morais Journal: J Cachexia Sarcopenia Muscle Date: 2010-12-17 Impact factor: 12.910
Authors: Amber S Kleckner; Eva Culakova; Ian R Kleckner; Elizabeth K Belcher; Wendy Demark-Wahnefried; Elizabeth A Parker; Gilbert D A Padula; Mary Ontko; Michelle C Janelsins; Karen M Mustian; Luke J Peppone Journal: Nutrients Date: 2021-12-31 Impact factor: 5.717
Authors: Lena Stockhoff; Theresa Muellner-Bucsics; Antoaneta A Markova; Marie Schultalbers; Simone A Keimburg; Tammo L Tergast; Jan B Hinrichs; Nicolas Simon; Svetlana Gerbel; Michael P Manns; Mattias Mandorfer; Markus Cornberg; Bernhard C Meyer; Heiner Wedemeyer; Thomas Reiberger; Benjamin Maasoumy Journal: Hepatol Commun Date: 2021-09-28